FDA Approves Samsung Bioepis' OSPOMYV™, XBRYK™ (denosumab-dssb), a Biosimilar to Prolia and Xgeva
Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for OSPOMYV™ (denosumab-dssb; SB16; 60 mg pre-filled syringe) and XBRYK™ (denosumab-dssb; SB16; 120 mg vial), biosimilars referencing Prolia and Xgeva respectively. In addition, the FDA granted a provisional determination for both Ospomyv and Xbryk's interchangeability designation.
OSPOMYV, referencing Prolia, has been approved for the treatment of postmenopausal women with osteoporosis at high risk for fracture, treatment to increase bone mass in men with osteoporosis at high risk for fracture, treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture, treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer and for the treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.
XBRYK, referencing Xgeva, has been approved for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors, treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity, and for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.
'The FDA approval of OSPOMYV and XBRYK marks a key step in improving patient access and alleviating treatment cost for patients with osteoporosis and cancer-related bone loss in the US. By providing quality-proven biosimilars, we are helping to address a critical healthcare need and reduce the burden of skeletal fractures that impact patients' quality of life,' said Byoungin Jung, Vice President and Regulatory Affairs Team Leader at Samsung Bioepis. 'This achievement underscores our commitment to healthcare innovation through biosimilars and our mission to meet the growing needs in critical therapeutic areas.'
The FDA approval was based on totality of evidence including analytical, non-clinical data, and clinical data. A randomized, double-blind, three-arm, parallel group, single-dose Phase 1 study demonstrated the pharmacokinetic (PK) equivalence between SB16, EU-sourced denosumab (EU-DEN), and US-sourced denosumab (US-DEN) in healthy male participants. The primary PK endpoints were met, in terms of area under the concentration-time curve (AUC) from time zero to infinity, AUC from time zero to the last quantifiable concentration, and maximum serum concentration. 1 In addition, a randomized, double-blind, multi-center Phase 3 study demonstrated equivalent efficacy and comparable safety, immunogenicity, PK, and pharmacodynamics (PD) profiles between SB16 and reference denosumab (DEN) in postmenopausal osteoporosis (PMO) patients. The primary endpoint was met in terms of percent (%) change from baseline in lumbar spine bone mineral density (BMD) at Month 12, and a follow-up up to Month 18 demonstrated switching to SB16 from DEN were comparable up to Month 18 in terms of efficacy, PK, PD, safety and immunogenicity. 2,3
OSPOMYV and XBRYK, marks Samsung Bioepis' 9 th and 10 th FDA approved medicines as well as the company's first FDA approval for an endocrinology biosimilar, setting another milestone for the company to broaden its biosimilar portfolio that cover a spectrum of therapeutic areas including immunology, oncology, ophthalmology, hematology and endocrinology.
OSPOMYV™ (denosumab-dssb) injection, for subcutaneous use
Ospomyv is a RANK ligand (RANKL) inhibitor indicated for treatment:
of postmenopausal women with osteoporosis at high risk for fracture
to increase bone mass in men with osteoporosis at high risk for fracture
of glucocorticoid-induced osteoporosis in men and women at high risk for fracture
to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer
SELECTED SAFETY INFORMATION
WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE
See full prescribing information for complete boxed warning.
Patients with advanced chronic kidney disease are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported.
The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia.
Prior to initiating Ospomyv in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Ospomyv in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD.
CONTRAINDICATIONS
Hypocalcemia
Pregnancy
Known hypersensitivity to denosumab products
WARNINGS AND PRECAUTIONS
Hypocalcemia: Pre-existing hypocalcemia must be corrected before initiating Ospomyv. May worsen, especially in patients with renal impairment. Adequately supplement all patients with calcium and vitamin D. Concomitant use of calcimimetic drugs may also worsen hypocalcemia risk. Evaluate for presence of chronic kidney disease mineral-bone disorder. Monitor serum calcium.
Same Active Ingredient: Patients receiving Ospomyv should not receive other denosumab products concomitantly.
Hypersensitivity including anaphylactic reactions may occur. Discontinue permanently if a clinically significant reaction occurs.
Osteonecrosis of the jaw: Has been reported with denosumab products. Monitor for symptoms.
Atypical femoral fractures: Have been reported. Evaluate patients with thigh or groin pain to rule out a femoral fracture.
Multiple vertebral fractures have been reported following treatment discontinuation. Patients should be transitioned to another antiresorptive agent if Ospomyv is discontinued.
Serious infections including skin infections: May occur, including those leading to hospitalization. Advise patients to seek prompt medical attention if they develop signs or symptoms of infection, including cellulitis.
Dermatologic reactions: Dermatitis, rashes, and eczema have been reported. Consider discontinuing Ospomyv if severe symptoms develop.
Severe bone, joint, muscle pain may occur. Discontinue use if severe symptoms develop.
Suppression of bone turnover: Significant suppression has been demonstrated. Monitor for consequences of bone over-suppression.
These highlights do not include all the information needed to use OSPOMYV safely and effectively. See full prescribing information for OSPOMYV HERE, which includes the Boxed Warning, Medication Guide and Instructions for Use.
XBRYK™ (denosumab-dssb) injection, for subcutaneous use
Xbryk is a RANK ligand (RANKL) inhibitor indicated for:
Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors.
Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.
SELECTED SAFETY INFORMATION
CONTRAINDICATIONS
Hypocalcemia
Known clinically significant hypersensitivity to denosumab products
WARNINGS AND PRECAUTIONS
Same Active Ingredient: Patients receiving Xbryk should not receive other denosumab products concomitantly.
Hypersensitivity reactions including anaphylaxis may occur. Discontinue permanently if a clinically significant reaction occurs.
Hypocalcemia: Denosumab products can cause severe symptomatic hypocalcemia. Fatal cases have been reported with denosumab products use. Correct hypocalcemia prior to initiating Xbryk. Monitor calcium levels during therapy, especially in the first weeks of initiating therapy, and adequately supplement all patients with calcium and vitamin D.
Osteonecrosis of the jaw (ONJ) has been reported in patients receiving denosumab products. Perform an oral examination prior to starting Xbryk. Monitor for symptoms. Avoid invasive dental procedures during treatment with Xbryk.
Atypical femoral fracture: Evaluate patients with thigh or groin pain to rule out a femoral fracture.
Hypercalcemia Following Treatment Discontinuation in Patients with Giant Cell Tumor of Bone and in Patients with Growing Skeletons: Monitor patients for signs and symptoms of hypercalcemia, and manage as clinically appropriate.
Multiple Vertebral Fractures (MVF) Following Treatment Discontinuation: When Xbryk treatment is discontinued, evaluate the individual patient's risk for vertebral fractures.
Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of potential risk to the fetus and to use effective contraception.
These highlights do not include all the information needed to use XBRYK safely and effectively. See full prescribing information for XBRYK HERE, which includes the Boxed Warning, Medication Guide and Instructions for Use.
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. For more information, please visit: www.samsungbioepis.com and follow us on social media – X, LinkedIn.
1 Lee HA, Kim S, Seo H, Kim S. A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects. Expert Opin Investig Drugs. 2023 Jul-Dec;32(10):959-966. doi: 10.1080/13543784.2023.2273510. Epub 2023 Nov 6. PMID: 37870163.
2 Langdahl B, Chung YS, Plebanski R, Czerwinski E, Dokoupilova E, Supronik J, Rosa J, Mydlak A, Rowińska-Osuch A, Baek KH, Urboniene A, Mordaka R, Ahn S, Rho YH, Ban J, Eastell R. Proposed Denosumab Biosimilar SB16 vs Reference Denosumab in Postmenopausal Osteoporosis: Phase 3 Results Up to Month 12. J Clin Endocrinol Metab. 2024 Sep 7:dgae611. doi: 10.1210/clinem/dgae611. Epub ahead of print. PMID: 39243386.
3 Richard Eastell, Bente Langdahl, Yoon-Sok Chung, Rafal Plebanski, Edward Czerwinski,Eva Dokoupilova, Jerzy Supronik, Jan Rosa, Andrzej Mydlak, Anna Rowinska-Osuch, Ki-Hyun Baek, Audrone Urboniene, Robert Mordaka, Sohui Ahn, Young Hee Rho, Jisuk Ban. A Randomized, Double-blind, Phase III Study to Compare SB16 (Proposed Denosumab Biosimilar) to Reference Denosumab in Patients with Postmenopausal Osteoporosis: 18-Month Results. Oral presentation at 2024 European Calcified Tissue Society (ECTS) Congress. May 25-28, 2024. Marseille, France.
SOURCE: Samsung Bioepis Co., Ltd.
Copyright Business Wire 2025.
PUB: 02/15/2025 06:07 PM/DISC: 02/15/2025 06:07 PM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Emulate Launches AVA™ Emulation System to Accelerate Drug Development With First-of-its-Kind High-Throughput Organ-Chip Platform
BOSTON--(BUSINESS WIRE)--Emulate, Inc., the world leader in Organ-on-a-Chip technology, today announced the commercial launch of the AVA™ Emulation System, a self-contained instrument that cultures, incubates, and images up to 96 independent Organ-Chip samples in a single run. AVA delivers an unprecedented magnitude of in vivo -level insights faster than animal models while cutting consumable costs four-fold and in-lab labor by half compared to current generation technologies. These transformative capabilities give the pharmaceutical industry the practical means to pivot beyond animal testing and into truly human-relevant territory. With the FDA targeting animal studies to become 'the exception rather than the norm,' the need for proven human models is urgent. Emulate's Liver-Chip S1—the first and only Organ-Chip admitted to the FDA's ISTAND program. Share 'AVA gives scientists unprecedented experimental capacity with the biological depth of live human tissue—something no other platform can match,' said Jim Corbett, Chief Executive Officer at Emulate. 'By combining Emulate's proven Organ-on-a-Chip technology with high-throughput consumables, automated imaging, and streamlined workflows in one benchtop unit, AVA lets teams ask bigger questions earlier and move the right drug candidates forward faster.' AVA Emulation System: Three Instruments in One AVA is the first self-contained Organ-on-a-Chip workstation to fuse high-throughput microfluidic tissue culture, full environmental control, and real-time imaging into a single, compact benchtop unit. Key performance gains include: Expanded experimental power – 96 independent Organ-Chip samples in a single run enable researchers to achieve microplate-level scale of their Organ-Chip experiments, enabling side-by-side comparison of dozens of compounds, doses, or stimuli. Lower operating costs – AVA achieves a four-fold drop in consumable spend and up to 50% fewer cells and media per sample compared to previous generation technology. Time & labor savings – Hands-on, in-lab time is reduced by more than half, thanks to automated microscopy, remote monitoring, and the revolutionary new Chip-Array™ consumable that integrates 12 independent Organ-Chips into an SBS format for streamlined workflows with multichannel pipettes and automated liquid handlers. AI-ready datasets – A typical 7-day experiment can generate >30,000 time-stamped data points from daily imaging and effluent assays, with post-takedown omics pushing the total into the millions—providing a rich, multi-modal foundation to feed machine-learning pipelines for target discovery, lead optimization, and safety prediction. A Timely Answer to Shifting Regulations With the FDA targeting animal studies to become 'the exception rather than the norm,' the need for proven human models is urgent. Emulate's Liver-Chip S1—the first and only Organ-Chip admitted to the FDA's ISTAND program—has already outperformed animals, showing 87% sensitivity and 100% specificity for drug-induced liver injury in a 2022 Communications Medicine study. AVA now scales that level of human relevance across discovery, efficacy, and toxicology screens, accelerating safer therapies through the pipeline. 'Moving towards reduction and in some cases replacement of animal models demands both biological fidelity and throughput,' noted Dr. Lorna Ewart, Emulate Chief Scientific Officer. 'AVA meets those dual requirements, empowering teams to rank-order lead candidates, pinpoint off-target toxicities, and advance safer therapies with unprecedented speed and confidence.' Broad Impact Across Industries In biopharma, this type of reduction and replacement is already a reality. A leading pharmaceutical company has demonstrated the power of implementing Organ-Chips into their development pipeline when one of their scientists saved millions of dollars and years of development time by using Emulate Liver-Chips ahead of non-human primates to screen lipid-nanoparticle (LNP) candidates. AVA's leap in throughput of predictive human biology stands to benefit not only biopharma but a wide spectrum of sectors that currently rely on inaccurate animal testing. Large pharmaceutical pipelines can now run comparable screens in a single AVA experiment, while smaller biotech teams gain enterprise-level capacity without adding headcount or infrastructure. Beyond therapeutics, contract research organizations, consumer-product companies, and environmental agencies can harness AVA to evaluate industrial chemicals, food additives, and cosmetic ingredients under human-relevant conditions—bringing faster, more ethical safety and efficacy decisions to market-driven and regulatory programs alike. Availability Global orders are open immediately. For pricing or demonstrations, please submit a request here. About Emulate Emulate, Inc. is the pioneer of Organ-on-a-Chip technology, enabling researchers to accurately replicate human tissue function and disease biology through next generation in vitro models. From target discovery to IND submission, Emulate aims to ignite a new era in human health research—one that reduces animal testing, cuts drug development costs, and accelerates the delivery of life-saving treatments. Emulate's Organ-Chip platforms, consumables, and organ models help the world's leading pharmaceutical, biotech, and academic teams generate human-relevant data that advance safer, more effective therapies. Learn more at
Business Upturn
3 hours ago
- Business Upturn
OneSource Specialty Pharma shares jump 3% after USFDA grants VAI classification for its Bangalore facility
By Aman Shukla Published on June 10, 2025, 09:22 IST Shares of OneSource Specialty Pharma Ltd jumped 3% in morning trade on June 10 after the company announced that its flagship facility in Bangalore received a 'Voluntary Action Indicated' (VAI) classification from the U.S. Food and Drug Administration (USFDA). As of 9:21 AM, the shares were trading 3.61% higter at Rs 2,002.70. The classification follows a routine USFDA inspection conducted from March 20 to March 28, 2025. At the end of the inspection, the agency issued a Form 483 with four observations. The company responded with a comprehensive corrective action plan. After reviewing the response, the USFDA designated the outcome as VAI, indicating that while issues were noted, they were not serious enough to trigger regulatory or enforcement action. The VAI status also confirms that the inspection is now officially closed. The company did not disclose the specific details of the observations, but emphasized that the facility remains integral to its core manufacturing and development operations. A VAI classification is generally seen as a positive regulatory outcome, especially compared to more severe classifications like 'Official Action Indicated' (OAI). Investors reacted favorably to the news, pushing the stock higher. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
3 hours ago
- Yahoo
Undiscovered Gems in Asia for June 2025
As global markets continue to navigate a landscape marked by cooling labor conditions and ongoing trade tensions, small-cap stocks have shown resilience, with indices like the Russell 2000 experiencing notable gains. Against this backdrop, the Asian market presents intriguing opportunities for investors seeking to uncover lesser-known companies that could benefit from regional economic dynamics and potential stimulus measures. Identifying promising stocks often involves looking for companies with strong fundamentals that can thrive despite broader market uncertainties. Name Debt To Equity Revenue Growth Earnings Growth Health Rating Hangzhou Xili Intelligent TechnologyLtd NA 11.73% 9.57% ★★★★★★ Wuxi Xinan Technology NA 11.99% 4.45% ★★★★★★ Hubei Three Gorges Tourism Group 11.24% -15.32% 17.90% ★★★★★★ Shanghai Guangdian Electric Group 0.37% -2.33% -33.49% ★★★★★★ Tohoku Steel NA 5.34% -2.26% ★★★★★★ Zhe Jiang Dayang Biotech Group 29.02% 8.38% -9.33% ★★★★★☆ ShenZhen QiangRui Precision Technology 18.68% 41.36% 14.12% ★★★★★☆ Lee's Pharmaceutical Holdings 13.81% -0.34% -27.47% ★★★★★☆ Hangzhou Zhengqiang 26.03% 2.95% 16.75% ★★★★★☆ Yukiguni Factory 134.59% -5.63% -32.04% ★★★★☆☆ Click here to see the full list of 2608 stocks from our Asian Undiscovered Gems With Strong Fundamentals screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Value Rating: ★★★★☆☆ Overview: Ningbo Lehui International Engineering Equipment Co., Ltd. operates in the engineering equipment sector and has a market cap of CN¥4.80 billion. Operations: The company generates revenue primarily from its engineering equipment segment. It has a market capitalization of CN¥4.80 billion, reflecting its valuation in the industry. The focus on this specific sector suggests targeted revenue streams aligned with engineering solutions. Ningbo Lehui, a notable player in the machinery sector, has seen its earnings grow by 64.9% over the past year, outpacing industry averages. Despite a volatile share price recently, it remains an attractive prospect as it's trading at 88.8% below estimated fair value. The company's net debt to equity ratio stands at a satisfactory 3.1%, though interest coverage is weak with EBIT covering only 1.8 times interest payments. Recent financials reveal net income of CNY 8.94 million for Q1 2025 and an annual dividend increase to CNY 0.40 per share, reflecting strong profitability and shareholder returns. Take a closer look at Ningbo Lehui International Engineering EquipmentLtd's potential here in our health report. Gain insights into Ningbo Lehui International Engineering EquipmentLtd's past trends and performance with our Past report. Simply Wall St Value Rating: ★★★★☆☆ Overview: Beijing Zhong Ke San Huan High-Tech Co., Ltd. operates in the high-tech industry and has a market capitalization of CN¥14.19 billion. Operations: Beijing Zhong Ke San Huan High-Tech generates revenue primarily through its operations in the high-tech sector, with a market capitalization of CN¥14.19 billion. Zhong Ke San Huan, a relatively small player in the tech industry, has shown a mixed financial performance. Over the past year, earnings surged by 64.7%, outpacing the electronic industry's growth of 2.7%. Despite this impressive growth, recent figures reveal challenges; Q1 2025 sales dropped to CNY 1.46 billion from CNY 1.65 billion a year earlier, though net income turned positive at CNY 13.49 million compared to a loss previously reported. The company trades at an attractive valuation—43% below its estimated fair value—and maintains more cash than total debt despite a rising debt-to-equity ratio now at 12.4%. Click to explore a detailed breakdown of our findings in Beijing Zhong Ke San Huan High-Tech's health report. Understand Beijing Zhong Ke San Huan High-Tech's track record by examining our Past report. Simply Wall St Value Rating: ★★★★★★ Overview: Goldsun Building Materials Co., Ltd. operates in the production and sale of premixed concrete, cement, and calcium silicate board across Taiwan and Mainland China, with a market capitalization of approximately NT$53.55 billion. Operations: Goldsun's primary revenue streams are derived from its Taiwan ready-mixed business, generating NT$18.89 billion, and its ready-mixed cement business in Mainland China, contributing NT$1.09 billion. Goldsun Building Materials, a promising player in the industry, has seen its earnings grow by 31.1% over the past year, outpacing the Basic Materials sector's 15.6%. The company's net debt to equity ratio is at a satisfactory 22.3%, reflecting prudent financial management as it decreased from 40.4% over five years. Despite a notable one-off gain of NT$930 million impacting recent results, Goldsun's Price-To-Earnings ratio of 11.6x remains attractive compared to Taiwan's market average of 18.5x. However, future earnings are projected to decline by an average of 16% annually for the next three years, which may temper investor enthusiasm despite recent dividend increases approved for TWD 2.8 per share. Unlock comprehensive insights into our analysis of Goldsun Building Materials stock in this health report. Learn about Goldsun Building Materials' historical performance. Click this link to deep-dive into the 2608 companies within our Asian Undiscovered Gems With Strong Fundamentals screener. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SHSE:603076 SZSE:000970 and TWSE:2504. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
